Reach out about this clinical trial
Contact Usor call 602-258-2863
COVID-19 tools and resources: symptom checker, safety measures, and visitor, testing and vaccine info. Learn more.
CONDITIONS: Glioblastoma, glioma, GBM - A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort